HA1 (ARHGAP45) Rabbit Polyclonal Antibody

CAT#: TA372703

ARHGAP45 rabbit polyclonal antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (1)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00

Specifications

Product Data
Applications IHC
Recommend Dilution IHC: 10-50
Positive control: Human breast cancer
Predicted cell location: Cytoplasm
Reactivity Human
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide of human ARHGAP45
Formulation pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Concentration lot specific
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C.
Gene Name histocompatibility (minor) HA-1
Background Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Synonyms HA-1; HLA-HA1; KIAA0223
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...